The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2024 | Tagraxofusp combined with azacitidine and venetoclax in the treatment of BPDCN and AML
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the combined use of tagraxofusp, azacitidine, and venetoclax for treating patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). He highlights a study showing promising results in patients with AML and myelodysplastic syndromes (MDS), with ongoing evaluation of this triplet combination in BPDCN. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Cimeio Therapeutics: Consultant; IDRx: Consultant; Jnana Therapeutics: Consultant; ProteinQure: Consultant; Qiagen: Consultant; Medzown: Stokeholder, SAB; AbbVie: Research Support; Stemline Therapeutics: Research Support.
